NYR nyrada inc.

10.0%

22.5¢

Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-18

First 18 Last

Share
Profile

Follow
Bendunstan

1,243 Posts.

158

23/10/24

12:38

Post #: 76260437
Share

Originally posted by zecs: ↑

1. ZERO HUMANS have been dosed right now! I plan on lifting weights in 4 weeks. Does that make me Mr Universe now?!
2. Passing GLP does not "derisk" phase 1 studies. GLP is mandatory. No Phase 1 study will start without passing GLP. Nothing is "derisked", otherwise why bother with Phase 1! Successfully completing phase 1 is the only thing that will "de risk" phase 1.
3. It doesn't do any of these things IN HUMANS. Dozens and dozens of preclinical compounds do this in rats, mice, and test tubes.
4. A patent "submitted" is not IP protection or a patent granted. Less than half of patents get approved. Patents take YEARS and YEARS.
5. OK, show us where the CEO has said they have locked in non dilutive funding. Be specific.
6. They've got less than 4 million in the bank,
7. So if anything this makes it more risky in safety and phase 1. More risk. Increased risk. Non de-risked risky McRisk with a side order of risk.
8. YES! You're getting it. Peers that have cleared phase 1, with a pipeline, IP protection, actual funding in place, without a track record of failure, are worth 100m. Nyrada is none of these things.

Expand

lol your a troll

AGN patented was granted with 7 months. Years and years. Grants patents for medical companies take 6-12 months maximum.

It’s like your story that Aptoll is 5 years ahead in Mycardial infarction when they are preclinical stage

4 million and 1 million rebate equals 5 million in cash.

Keep posting troll comments because your trolling a 20 million market cap.

How does it feel to sell at 5 cents like you did. Relax let the company do its thing human safety clearence is around the corner

Last edited by Bendunstan: 23/10/24

NYR Price at posting: 14.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

First 18 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 22.5¢		Change -0.025(10.0%)		Mkt cap ! $47.45M

Open	High	Low	Value	Volume
25.0¢	25.0¢	22.5¢	$209.3K	892.7K

Buyers (Bids)

No.	Vol.	Price($)
1	7150	22.5¢

Sellers (Offers)

Price($)	Vol.	No.
24.0¢	416666	1

View Market Depth

No.	Vol.	Price($)
3	157420	0.220
2	120005	0.215
4	170000	0.210
1	30000	0.205
3	119346	0.200

Price($)	Vol.	No.
0.240	416666	1
0.245	5000	1
0.250	38461	1
0.255	25000	1
0.260	54498	2

Last trade - 16.10pm 27/06/2025 (20 minute delay)

NYR (ASX) Chart

Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-18

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Monash IVF shares cater 25% – Disaster or deep-value play?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-18

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Monash IVF shares cater 25% – Disaster or deep-value play?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News